Symptomtext
inadvertently administered with an expired product with no reported adverse event; Initial information received on 23-Mar-2022 regarding an unsolicited valid non-serious case received from a healthcare professional. This case involves a 48-year-old male patient who was inadvertently administered with an expired product of vaccine DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE [ADACEL] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 23-Mar-2022, the patient received a dose of 0.25 ml to 2 ml suspect DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE (frequency: once) (strength, formulation: unknown) (lot number: U6621BA and Expiration Date: 21-Mar-2022) via intramuscular route in the left deltoid for Immunization. On 23- Mar-2022 the patient had non-serious event, "inadvertently administered with an expired product with no reported adverse event" (expired product administered) following the administration of DIPHTHERIA-2/TETANUS/5 AC PERTUSSIS VACCINE. It was reported, "RN requesting information regarding ADACEL PFS. The product was inadvertently administered with an expired product to an employee. Patient Information o Patient age <1 year enter as 2m, 4m, etc. Many pediatric vaccines need month for age. 48 YEARS. Dosage Information o Frequency = once ONCE o Therapy Date: From = Date of immunization To = leave blank 23Mar2022 o Route = route & site INTRAMUSCULAR, LEFT DELTOID o Dose = 0.25 mL to 2 mL for vaccines or 0.1 mL for TB skin test 0.25mL o Strength = standard except for Fluzone HD o Indications = Immunization or TB skin test. Event Information o Treatment ADACEL." Action taken: Not applicable. Outcome: Unknown This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.